1. Introduction
This year, over 54,000 new cases of oral/pharyngeal cancer, as well as nearly 2 million new cancer cases, are projected to be diagnosed in the United States [ 1 ]. As dental practitioners, we are likely to encounter these oncology patients as pre-diagnosed, newly diagnosed, or post-oncologic treated patients. This narrative review will address the role of a dentist in the management of head and neck radiation oncology patients and medical oncology patients.
Part 1: The Head and Neck Radiation Oncology Patient
The majority of head and neck cancer cases include squamous cell carcinoma of the oral cavity and oropharynx ( Figure 1 and Figure 2 ). These tumors are unified by a common anatomy and can be difficult to manage due to their proximity to vital structures. Head and neck cancer patients regularly undergo radiation therapy (RT) either as a primary or adjuvant therapy in combination with one or more modalities, such as chemotherapy and/or surgery. Treatment field planning is a critical part of RT management of head and neck cancer. The plans are drawn using computed tomography images to encompass the gross extent of the tumor, areas of potential microscopic involvement, high risk lymph nodes, patient motion, and setup error [ 2 ] ( Figure 3 and Figure 4 ). Therapeutic RT standard fractionation for head and neck cancer entails two Gy per fraction, given five fractions per week, for 30–35 fractions [ 2 ].
There have been technological advances in radiation delivery techniques from conventional/2D techniques to 3D-conformal RT to intensity-modulated radiation therapy (IMRT)/proton beam radiation therapy (PBRT). These advanced techniques (IMRT and PBRT) enable improved tumor dose conformality and tissue/organ sparing capability [ 2 , 3 , 4 , 5 ]. Although IMRT and PBRT can reduce the risk of radiotherapy-related toxicities such as mucositis, trismus, xerostomia/hyposalivation, osteoradionecrosis (ORN) and abnormal development of orofacial structures, patients can still suffer from these complications, resulting in a decrease in quality of life [ 2 , 6 , 7 , 8 , 9 , 10 , 11 ].
1.1. Oral Mucositis
Mucositis is the inflammation of the mucosa, associated with thinning and apoptosis/necrosis of the mucosa ( Figure 5 ). It is the most common acute complication of head and neck RT. The etiology of mucositis is the effect of radiation on mucosal cells. Radiation breaks the double-stranded DNA of the cells, resulting in lethal damage [ 12 ]. Oral mucositis (OM) is characterized by pain, erosions, ulcerations, odynophagia, secondary infections, reduced oral intake and, in severe cases, the necessity for a feeding tube or total parenteral nutrition. OM usually develops 2 weeks after the initiation of head and neck RT and may persist for 6 months after completion of RT. Almost all patients receiving head and neck radiation +/− chemotherapy develop oral mucositis.
Oral mucositis can be graded using the WHO toxicity scale:
Grade one—Soreness ± erythema.
Grade two—Erythema + Ulcers; patient can swallow food.
Grade three—Extensive erythema/ulceration; patient cannot swallow food.
Grade four—Extensive erythema/ulceration; oral nourishment impossible (life threatening).
Grades three and four are considered severe mucositis. Of the patients with severe oral mucositis, 70% require feeding tubes and 62% of these patients require hospitalization for total parenteral nutrition, intravenous analgesia and intravenous antibiotics [ 13 ]. Cessation of RT or a reduction in radiation dose is required by 35% of patients due to severe oral mucositis, which then increases the risk of tumor recurrence or treatment failure [ 13 ].
Prevention and Management of Oral Mucositis
Amifostine is a chemoradioprotective drug approved by the Food and Drug Administration (FDA) to help reduce the severity of mucositis in patients undergoing adjuvant chemo-RT for head and neck cancer. However, amifostine is limited in its use due to its associated severe side effects such as rapid hypotension, nausea, vomiting and a narrow therapeutic window related to its rapid systemic clearance [ 14 , 15 ]. The use of PBRT for head and neck cancer has been shown to reduce the rates of acute complications such as mucositis, nausea, dysgeusia and fatigue compared with IMRT [ 2 ]. Systematic reviews and meta-analyses on photobiomodulation (low-level laser therapy) in preventing and treating severe oral mucositis concluded that it significantly reduces the rate of this acute complication in chemotherapy and radiotherapy patients [ 16 , 17 ]. Cryotherapy has been shown to be effective in preventing severe oral mucositis, and it has been suggested that the combination of photobiomodulation and cryotherapy would be more beneficial for patients [ 18 , 19 ]. Topical analgesic rinses and anti-inflammatory and coating agents for pain control enable patients to eat, and antimicrobials aid patients at risk for infection. The Adapted Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Oral Oncology (ISOO) clinical practice guidelines for oral mucositis are presented in Table 1 [ 20 ].
1.2. Trismus
Trismus is a well-known complication of radiation therapy [ 21 , 22 ] ( Figure 6 ). It is defined as an inability to open the mouth or difficulty with mouth opening secondary to spasm of the muscles of mastication. Normal mouth opening (maximal interincisal opening) in the healthy population ranges from 36 to 55 mm. Measurements < 35 mm are considered to be trismus [ 23 ]. Trismus is associated with difficulty in many aspects of daily living such as eating, maintaining oral hygiene, receiving dental treatment, as well as impaired speech [ 24 , 25 , 26 ].
The prevalence of trismus among head and neck cancer patients managed with IMRT ranges from 4% to 77.3% [ 27 , 28 , 29 , 30 , 31 ]. Risk factors for the development of trismus include smaller pre-RT maximal interincisal opening and increased radiation dose to the muscles of mastication [ 7 , 32 , 33 , 34 ]. A study showed that patients with pre-RT MIO measurements of ≤40 mm were at risk of developing trismus, and the study by Teugh et al. reported that for every additional 10 Gy of radiation to the medial pterygoid muscle there was a 24% probability of developing trismus [ 7 , 34 ]. It is important to note that most patients typically present with limited mouth opening secondary to mucositis and not due to the radiation-related soft tissue fibrosis in trismus. Therefore, trismus can be either an acute or a chronic problem, depending on the etiology.
Prevention and Management of Trismus
Management of trismus is challenging, so practitioners should focus on prevention. The patient should be informed about this possible complication during a pre-RT dental appointment, as well as the need to perform regular mouth opening jaw exercises throughout the course of their RT [ 35 , 36 ]. Conservative management of trismus includes the use of jaw opening devices such as TheraBite, Dynasplint, corkscrews and stacked tongue depressors [ 37 , 38 ].
1.3. Xerostomia/Hyposalivation
Xerostomia is the most common long-term complication seen in head and neck cancer patients following RT [ 39 , 40 ]. The terms xerostomia and hyposalivation are frequently used interchangeably. However, xerostomia is a subjective assessment reported by patients as dry mouth and/or an altered taste. Hyposalivation is an objective assessment of reduction in salivary flow. This condition often limits the quality of life of patients regarding difficulty with mastication, speech, swallowing, halitosis, oral hygiene and dental caries.
The etiology of RT-induced xerostomia has been attributed to apoptosis or membrane damage-induced dysfunction of the salivary gland acinar cells and the inability of the damaged stem/progenitor cells to replace the apoptotic acinar cells [ 41 , 42 ]. The main risk factor for the development of RT-induced xerostomia is the dose of radiation to the salivary glands. Studies have reported a minimal salivary gland dysfunction at a mean dose (Dmean) of <10 Gy to the salivary gland, and at Dmean > 40 Gy there is complete salivary gland dysfunction [ 43 , 44 , 45 ]. Higher RT doses to the parotid glands predispose patients to xerostomia, although some patients may gradually recover within 24 months [ 8 , 43 , 45 , 46 , 47 ]. A study by Owosho et al. demonstrated that the rate of RT-induced xerostomia was highest within the first 6 months after treatment and is reduced at longer follow-up times [ 8 ]. The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) guidelines were developed to minimize the risk of salivary gland dysfunction either by: (i) one of the parotid glands receives a Dmean <~20 Gy; or (ii) both parotid glands receive a Dmean <~25 Gy. This has been shown to be effective in preventing the development of severe xerostomia [ 8 , 46 , 47 ].
Prevention and Management of RT-Induced Xerostomia
As noted earlier, amifostine is a chemoradioprotective drug approved by the FDA to help prevent moderate to severe xerostomia in patients undergoing adjuvant chemo-RT for head and neck cancer. However, amifostine is limited in its use because of its associated severe side effects listed above [ 14 , 15 ].
Xerostomia can be managed with parasympathomimetics such as pilocarpine and cevimeline. A systematic review and meta-analysis on the efficacy and safety of pilocarpine determined that pilocarpine was better than a placebo for the symptomatic treatment of radiation-induced xerostomia in patients with head and neck cancer [ 48 ]. Salivary flow stimulants and saliva substitutes or oral lubricants such as sugarless chewing gum, Biotène mouth oral rinse or moisturizing spray, ACT total care dry mouth mouthwash, XyliDent, sipping water and sucking on ice chips are also adjunct treatments. Patients with xerostomia should be prescribed an aggressive fluoride regimen and followed closely to help prevent and/or identify incipient dental caries. Adapted clinical recommendation guidelines by ISOO/MASCC/American Society of Clinical Oncology (ASCO) on xerostomia induced by nonsurgical cancer therapies are presented in Table 2 [ 49 ].
1.4. Osteoradionecrosis
ORN is the most severe complication encountered by head and neck cancer patients following radiation. ORN is defined as an area of exposed necrotic bone in a previously irradiated area that fails to heal over a period of 3–6 months [ 50 , 51 ] ( Figure 7 and Figure 8 ). Cases of radiographic ORN with intact mucosa have been described [ 52 , 53 ]. The etiology of ORN has been attributed to the avascular effect of radiation to the bone, resulting in hypoxia, hypovascularity and hypocellularity [ 50 ]. The risk factors for the development of ORN can be broadly divided into local factors such as radiation dose, radiation field, proximity of tumor to bone, poor oral hygiene (periodontitis) and trauma (such as dental extractions and dentoalveolar surgery). Systemic factors include immunodeficient status, co-morbidities, smoking and alcohol use [ 10 , 54 , 55 , 56 , 57 , 58 ]. Radiation to the head and neck has been shown to increase periodontal attachment loss, resulting in mobile teeth, spontaneous exfoliation of teeth and non-exposed breakdown of alveolar bone.
ORN of the jaw is graded as follows:
Grade zero—Radiographic ORN with intact mucosa.
Grade one—Exposed necrotic bone without signs of infection for at least 3 months.
Grade two—Exposed necrotic bone with signs of infection or sequestrum, but not grades three and four.
Grade three—ORN resulting in pathologic fracture or ORN treated with successful surgical resection.
Grade four—ORN refractory to surgical resection.
The prevalence of ORN in the era of IMRT ranges from 4.3% to 6.8% [ 10 , 59 , 60 ]. Fortunately, the prevalence of ORN has decreased over recent decades. This reduction in prevalence is attributed to the advances in radiation delivery techniques. When comparing 3D conformal RT to IMRT, Tsai et al. showed a reduction in ORN from 13% to 6% [ 59 ]. However, it is important to note that a recent first study to evaluate the prevalence of ORN in head and neck cancer patients treated with PBRT reported a prevalence of 10.6% (13/122) [ 9 ]. The primary tumor sites for the 13 patients that developed ORN ranged from the base of tongue, tonsil, buccal mucosa, floor of mouth, hard palate, retromolar trigone and maxillary alveolus. All 13 patients reported no precipitating trauma (dental extraction or dentoalveolar surgery). This is of interest because PBRT is reported to demonstrate a greater tissue sparing capability than IMRT, which is attributed to the inert property of proton particles, known as Bragg peak , that allows deposition of its energy over a discrete range, thereby eliminating an exit dose to surrounding adjacent structures [ 61 ]. An earlier study on PBRT for the management of head and neck cancer patients reported lower rates of acute complications such as mucositis, nausea, dysgeusia and fatigue compared with IMRT [ 2 ].
High radiation dose remains the major risk factor for ORN. Studies have shown that radiation doses of >60 Gy to the bone are closely related to the risk of developing ORN [ 10 , 62 ]. A study evaluating the prevalence of ORN in head and neck cancer patients treated with IMRT reported that 96% of the ORN-affected sites received over 60 Gy (Dmax: 44.3 Gy–80.9 Gy) [ 10 ]. Another study by Singh et al. evaluating the prevalence of ORN following PBRT for head and neck cancer patients reported that all ORN-affected sites received over 60 Gy (Dmax: 61.8 Gy–81.2 Gy) [ 9 ].
Prevention and Management of Osteoradionecrosis
Managing ORN can be very challenging; thus, focusing on prevention is paramount. All patients who are scheduled to undergo RT for head and neck cancer should have a comprehensive dental evaluation. During this pre-RT dental evaluation, patients should be counseled on the possible oral complications of RT as well as preventive techniques. A comprehensive oral examination should be performed including panoramic and bitewing radiographs (and periapical radiographs when indicated). Prophylaxis (dental cleaning), topical fluoride application and detailed oral hygiene instructions are indicated at this time. Dental caries and periodontal disease should be treated as soon as possible. Indicated dental extractions (for non-restorable and unsalvageable periodontally involved teeth) should be completed at least 2 weeks prior to the commencement of RT. In addition, a prescription for high potency fluoridated toothpaste should be issued. Patients should be re-evaluated at mid-RT, at the completion of RT, periodically every 3 months for the first year and every 6 months, thereafter.
Invasive dental procedures such as extractions, deep root planing and implant placement should be avoided as much as possible after head and neck RT. If invasive dental procedures are necessary, the amount of radiation to the region of the jaw involved should be dosimetrically calculated. Extraction in an area of the jaw with a maximum dose point of >50 Gy is discouraged. Endodontic treatments are recommended. Decoronation of the tooth and root canal treatment of the retained root is encouraged.
There is no standard protocol in the management of ORN. Many different therapeutic approaches have been utilized based on the grade at presentation: chlorhexidine (wound care) rinse for local debridement; antibiotic and pain medications when indicated until the exposed necrotic bone is loose and can be passively removed; hyperbaric oxygen (which may require dives before and/or after the invasive dental procedure); pentoxifylline and tocopherol +/− antibiotics; photobiomodulation (low-level laser therapy); teriparatide; and surgical options (alveolectomy, maxillectomy or resection) [ 63 , 64 , 65 , 66 ]. In our experience, head and neck surgical oncologists now consider the use of pentoxifylline and tocopherol protocol as the typical first line management for ORN, and it has decreased the rate of major surgical resection and reconstruction.
1.5. Abnormal Development of Orofacial Structures
Radiotherapy to the head and neck of children can potentially lead to abnormal development of orofacial structures. Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma, accounting for 5–8% of all childhood malignancies, and the head and neck is the most common location for RMS [ 67 ]. Management of RMS includes surgery, chemotherapy, and radiotherapy.
The following late sequelae of RT-related toxicities to the orofacial structures in children have been reported: facial asymmetry secondary to jaw hypoplasia; tooth agenesis/hypodontia/oligodontia; and root agenesis/shortening/malformation [ 68 , 69 , 70 ]. Reports of these complications have persisted even in the era of IMRT [ 11 ]. The severity of the orofacial developmental abnormalities is related to the age of the child at treatment, the tumor/therapy site and the dose of radiation [ 11 , 71 ]. Younger children face greater risk and severity of orofacial developmental abnormalities. Kaste et al. reported that a radiation dose > 20 Gy to the orofacial region of children places them at a 4–10-fold higher risk of developing dental abnormalities [ 71 ]. Ameloblasts (tooth-forming progenitor cells) are damaged at a radiation dose of 10 Gy, and at 30 Gy tooth development is completely halted [ 72 ].
Prevention and Management of Abnormal Development of Orofacial Structures
Prevention of this late sequelae of RT for pediatric head and neck cancer may not be possible, as sparing these structures from the risk of radiation without compromising locoregional cancer control is challenging. However, a pediatric dentist should be integrated in the care of children with head and neck cancers for close surveillance and management of these complications.
Part 2: The Medical Oncology Patient
This second part of the review article will address the role of a dentist in the management of medical oncology patients.
2. Oncology Patients on Antiresorptive/Antiangiogenic Medications
The most common cancers in males and females in the United States are prostate and breast cancers, respectively [ 1 ]. Advanced stages of many malignancies are associated with metastases to bone. Multiple myeloma and metastatic bone disease may necessitate the use of bone-modifying agents, such as antiresorptive medications, including intravenous bisphosphonates (pamidronate and zoledronate) and humanized monoclonal anti-RANK ligand (denosumab). These bone-modifying agents help in the prevention of skeletal-related events such as: spinal bone compression, bone fracture and surgery, as well as radiotherapy to bone [ 73 , 74 ]. These antiresorptive medications alongside other oncologic medications, including tyrosine kinase inhibitors (sunitinib and imatinib), monoclonal antibodies (bevacizumab), mTOR inhibitors (everolimus), anti-CTLA4 (ipilimumab), fusion protein (ziv-aflibercept) and immunosuppressants (methotrexate and corticosteroids), are reported to be associated with medication-related osteonecrosis of the jaw (MRONJ) [ 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ].
MRONJ is defined as an area of exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in the maxillofacial region that has persisted for more than 8 weeks in an area not previously irradiated or metastases to the bone, in a patient with a history of treatment with antiresorptive therapy alone or in combination with immune modulators or antiangiogenic medication [ 82 ]. The etiology of MRONJ is multifactorial, including bone remodeling inhibition, inflammation or infection, angiogenesis inhibition, innate or acquired immune dysfunction and genetic predisposition [ 82 ].
The risk factors for the development of MRONJ can be broadly divided into three local factors: dentoalveolar trauma (such as extractions and dentoalveolar surgery), poor oral hygiene (periodontitis) and anatomic location (mandible > maxilla) [ 83 , 84 , 85 ]. Systemic factors include age (older patients), gender (F > M), co-morbidities, smoking and corticosteroids [ 85 , 86 ]. The risk of developing MRONJ after a tooth extraction among cancer patients taking antiresorptive medications ranges from 1.6% to 14.8% [ 87 , 88 , 89 ]. It is important to note that cases of MRONJ without a precipitating dental trauma have been reported as occurring spontaneously [ 83 ].
MRONJ is staged as follows [ 82 ]:
Stage zero—Clinical/radiographic MRONJ with intact mucosa, no exposed necrotic bone.
Stage one—Exposed necrotic bone or fistula that probes to bone without signs of infection.
Stage two—Exposed necrotic bone or fistula that probes to bone with signs of infection or sequestrum.
Stage three—Exposed necrotic bone or fistula that probes to bone with signs of infection or sequestrum. In addition, one or more of the following: exposed necrotic bone extending beyond the region of alveolar bone, pathologic fracture, extraoral fistula, oral antral/oral–nasal communication and osteolysis extending to the inferior border of the mandible or sinus floor.
The risk of MRONJ is significantly greater in cancer patients receiving antiresorptive therapy compared with patients receiving antiresorptive therapy for osteoporosis. This disparity is due to differences in the dose, frequency of use and mode of administration of the antiresorptive medications. The risk of MRONJ amongst oncology patients taking zoledronate ranges from 0 to 18%, with most studies reporting < 5%, and that for oncology patients taking denosumab ranges from 0 to 6.9%, with most studies reporting < 5% [ 82 , 90 , 91 , 92 ]. Oncology patients on denosumab are at risk of developing MRONJ earlier. A study reported that cancer patients using denosumab developed MRONJ earlier or at fewer doses compared with cancer patients using intravenous bisphosphonates (pamidronate or zoledronate) [ 83 ].
2.1. Prevention and Management of MRONJ
The role of pre-medication dental evaluation (PMDE) in prevention of MRONJ has been shown to be very effective in reducing the incidence of MRONJ among oncology patients using antiresorptive/antiangiogenic medications. The study by Owosho et al. showed a 12-fold decrease in the incidence of MRONJ among oncology patients who received PMDE compared with patients who did not receive PMDE [ 83 ]. Studies by Bramati et al. and Bonacina et al. with 212 and 282 patients, respectively, demonstrated a reduction in the incidence of MRONJ from 8.6% and 10.8%, respectively, to 0% after implementing PMDE [ 93 , 94 ]. Similar studies by Dimopoulos et al. and Ripamonti et al. reported similar outcomes of lesser incidence of MRONJ in patients that received PMDE [ 95 , 96 ].
PMDE entails patient education, comprehensive dental evaluation, and completion of recommended dental treatment [ 83 ]. During the PMDE visit, oncology patients should be informed about the potential oral complication of MRONJ and the need to avoid any form of invasive dental procedures after commencing the antiresorptive/antiangiogenic medications. In addition, patients are provided oral hygiene instructions and nutritional counselling. A comprehensive dental examination should be performed including panoramic and bitewing radiographs, (and periapical radiographs when indicated). Prophylaxis (dental cleaning) and topical fluoride application are indicated as well. Dental caries and periodontal disease should be treated as soon as possible. Indicated dental extractions (non-restorable and periodontally involved teeth) should be completed at least 2–3 weeks prior to the commencement of antiresorptive/antiangiogenic medications. In addition, a prescription for high potency fluoridated toothpaste should be provided. Patients should be periodically evaluated every 3 months for the first year and every 6 months, thereafter. The American Association of Oral and Maxillofacial Surgeons’ position paper on MRONJ—2022 Update states that the clinical utility of drug holidays to mitigate MRONJ risk in patients undergoing dentoalveolar surgery remains controversial [ 82 ].
There are different management approaches to MRONJ based on the stage at presentation: chlorhexidine (wound care) rinse for local debridement and antibiotic and pain medications when indicated until the exposed necrotic bone is loose and can be passively removed. The use of other non-surgical options, such as pentoxifylline and tocopherol +/− antibiotics; photobiomodulation (low-level laser therapy); and teriparatide have shown great promise as effective management adjuncts [ 97 , 98 , 99 , 100 , 101 ]. Due to the unpredictable, protracted course and varying success rates of non-surgical approaches in the management of MRONJ, surgical options (alveolectomy, maxillectomy or resection [marginal or segmental]) should be considered in the management of MRONJ. Surgical options have reported high success rates [ 82 ]. Adapted MASCC/ISOO/ASCO clinical practice guidelines for MRONJ are presented in Table 3 [ 102 ].
2.2. Hematopoietic Stem Cell Transplant (HSCT)
Hematopoietic stem cell transplant (HSCT) is widely used in the management of malignant and non-malignant hematologic diseases, such as leukemia, lymphoma, multiple myeloma, aplastic anemia and immune deficiency disorders for the purpose of immune system reconstitution following conditioning. This form of oncologic therapy renders patients severely immunocompromised and at risk of bleeding prior to, during and long after the therapy, secondary to cytopenia and thrombocytopenia [ 103 ]. During this period of immunosuppression, patients are at an increased risk of infection with potential for systemic spread. Poor oral health predisposes patients to bacteremia, and odontogenic infections can become severe enough to contribute to morbidity and mortality [ 104 ]. HSCT (conditioning) also causes mucositis and salivary gland dysfunction (xerostomia) [ 105 , 106 ]. Oral mucositis usually begins a week after initiation of conditioning and continues for two weeks after the end of conditioning. Another complication that arises after allogeneic HSCT is chronic graft-versus-host disease (cGVHD), which occurs within several months after HSCT in a high percentage of patients. cGVHD affects multiple organs, including the skin, eyes, gastrointestinal tract-oral cavity, lungs and liver [ 107 ]. Oral cGVHD is characterized by ulcers, erythematous and lichenoid lesions [ 108 ].
For the aforementioned reasons, pre-HSCT dental clearance with an established dental clearance protocol should be incorporated in the management of these patients. The National Cancer Institute, Centers for Disease Control and Prevention, the joint taskforce of the Multinational Association for Supportive Care in Cancer with the International Society of Oral Oncology and the European Society for Blood and Marrow Transplantation have all recommended dental clearance prior to undergoing HSCT. Pre-HSCT includes a comprehensive oral evaluation and completion of recommended dental treatment. A comprehensive oral examination should be performed, including panoramic and bitewing radiographs (and periapical radiographs when indicated), for evaluation of dental caries, periapical/periodontal/bone pathologies, and the status of the third molars. Following the oral evaluation, the recommended dental therapies such as caries control, endodontic therapy, periodontal therapy (prophylaxis, scaling and root planing) and topical fluoride application are to be completed as soon as possible. Indicated dental extractions for non-restorable and unsalvageable periodontally involved teeth should be completed at least 2 weeks prior to the commencement of HSCT/high-dose chemotherapy. In addition, a prescription for high potency fluoridated toothpaste should be provided.
The timing of dental procedures during the pre-HSCT dental clearance in these patients should be coordinated with the medical team. The patient’s hematologic laboratory result should be reviewed for complete blood count (white blood cell count, absolute neutrophil count [ANC] and platelet count) before performing any dental procedures to avert the risk of infection and bleeding. A patient with severe neutropenia (ANC: 0–499) is at risk of life-threatening infection and should be isolated and hospitalized. The only treatment that should be performed is palliative care under antibiotic prophylaxis, oral antimicrobial rinse, and post-procedural antibiotic regimen for a week. No routine care should be completed on these patients. Patients with moderate neutropenia (ANC: 500–999) are at a moderate risk for infection. They should be given antibiotic prophylaxis, oral antimicrobial rinse before any dental procedure and post-procedural antibiotic regimen for 5 days. While patients with mild neutropenia (ANC: 1000–1500) are at a mild risk for infection, they can receive routine dental care without antibiotic prophylaxis (except in instances of major surgery, such as multiple dental extractions) and post-procedural antibiotic regimen for 5 days. Patients with a platelet count of <50,000 should not receive any invasive dental procedure due to the risk of uncontrollable bleeding. At platelet counts < 20,000, the patient may bleed spontaneously.
The acute complications of oral mucositis and xerostomia can be managed as described earlier in the first part of this review article.
2.3. Immune Checkpoint Inhibitors (Immunotherapy)
Immune checkpoint inhibitors such as anti-CTLA4 (Ipilimumab) and PD-1 inhibitors (Pembrolizumab and Nivolumab) are now used in the management of several advanced cancers. PD-1 inhibitors have been approved by the FDA for a subset of patients with advanced head and neck cancer. The following oral toxicities of these immune checkpoint inhibitors have been reported: xerostomia, dysgeusia, mucositis, lichenoid reaction and MRONJ [ 78 , 109 , 110 , 111 ].
3. Conclusions
As dental practitioners, we play a crucial role in the management of the head and neck radiation oncology/medical oncology patients, from making the initial diagnosis of the oral/oropharyngeal cancer to the identification and management of the associated oncologic therapy complications. Pre-radiation therapy/antiresorptive/antiangiogenic medications and pre-HSCT dental evaluation is an essential management step in the prevention and management of these complications. Each comprehensive head and neck/medical oncology team should have a dentist integrated in the care of these oncology patients.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Author Contributions
Conceptualization, A.A.O.; methodology, A.A.O.; software, A.A.O.; validation, A.A.O., K.D., B.H., B.C.W., R.E.S., J.P.G. and D.L.S.; resources, A.A.O., K.D., B.H., B.C.W., R.E.S., J.P.G. and D.L.S.; data curation, A.A.O., K.D., B.H., B.C.W., R.E.S., J.P.G. and D.L.S.; writing—original draft preparation, A.A.O.; writing—review and editing, A.A.O., K.D., B.H., B.C.W., R.E.S., J.P.G. and D.L.S.; project administration, A.A.O. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
No data.
Conflicts of Interest
All authors declare that there are no financial conflict associated with this study and that the funding source had no role in conceiving and performing the study.
References
1. Siegel R.L. Miller K.D. Wagle N.S. Jemal A. Cancer statistics, 2023 CA Cancer J. Clin. 2023 73 17 48 10.3322/caac.21763 36633525
2. Romesser P.B. Cahlon O. Scher E. Zhou Y. Berry S.L. Rybkin A. Sine K.M. Tang S. Sherman E.J. Wong R. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation Radiother. Oncol. 2016 118 286 292 10.1016/j.radonc.2015.12.008 26867969 PMC4980117
3. Lohia S. Rajapurkar M. Nguyen S.A. Sharma A.K. Gillespie M.B. Day T.A. A comparison of outcomes using intensity-modulated radiation therapy and 3-dimensional conformal radiation therapy in treatment of oropharyngeal cancer JAMA Otolaryngol. Head Neck Surg. 2014 140 331 337 10.1001/jamaoto.2013.6777 24557509
4. Simone C.B. 2nd Ly D. Dan T.D. Ondos J. Ning H. Belard A. O’Connell J. Miller R.W. Simone N.L. Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer Radiother. Oncol. 2011 101 376 382 10.1016/j.radonc.2011.05.028 21663988 PMC3174314
5. Owosho A.A. Yom S.K. Han Z. Sine K. Lee N.Y. Huryn J.M. Estilo C.L. Comparison of mean radiation dose and dosimetric distribution to tooth-bearing regions of the mandible associated with proton beam radiation therapy and intensity-modulated radiation therapy for ipsilateral head and neck tumor Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2016 122 566 571 10.1016/j.oooo.2016.07.003 27765327 PMC5279063
6. Franco P. Martini S. Di Muzio J. Cavallin C. Arcadipane F. Rampino M. Ostellino O. Pecorari G. Garzino Demo P. Fasolis M. Prospective assessment of oral mucositis and its impact on quality of life and patient-reported outcomes during radiotherapy for head and neck cancer Med. Oncol. 2017 34 81 10.1007/s12032-017-0950-1 28386836
7. Owosho A.A. Pedreira Ramalho L.M. Rosenberg H.I. Yom S.K. Drill E. Riedel E. Tsai C.J. Lee N.Y. Huryn J.M. Estilo C.L. Objective assessment of trismus in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT) J. Cranio-Maxillofac. Surg. 2016 44 1408 1413 10.1016/j.jcms.2016.06.008 PMC5279066 27377999
8. Owosho A.A. Thor M. Oh J.H. Riaz N. Tsai C.J. Rosenberg H. Varthis S. Yom S.H. Huryn J.M. Lee N.Y. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines J. Cranio-Maxillofac. Surg. 2017 45 595 600 10.1016/j.jcms.2017.01.020 PMC6619497 28256385
9. Singh A. Kitpanit S. Neal B. Yorke E. White C. Yom S.K. Randazzo J.D. Wong R.J. Huryn J.M. Tsai C.J. Osteoradionecrosis of the Jaw Following Proton Radiation Therapy for Patients with Head and Neck Cancer JAMA Otolaryngol. Head Neck Surg. 2022 149 151 10.1001/jamaoto.2022.4165 PMC9912132 36547968
10. Owosho A.A. Tsai C.J. Lee R.S. Freymiller H. Kadempour A. Varthis S. Sax A.Z. Rosen E.B. Yom S.K. Randazzo J. The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience Oral Oncol. 2017 64 44 51 10.1016/j.oraloncology.2016.11.015 28024723 PMC5560021
11. Owosho A.A. Brady P. Wolden S.L. Wexler L.H. Antonescu C.R. Huryn J.M. Estilo C.L. Long-term effect of chemotherapy-intensity-modulated radiation therapy (chemo-IMRT) on dentofacial development in head and neck rhabdomyosarcoma patients Pediatr. Hematol. Oncol. 2016 33 383 392 10.1080/08880018.2016.1219797 27689858 PMC5175398
12. Sonis S.T. The pathobiology of mucositis Nat. Rev. Cancer 2004 4 277 284 10.1038/nrc1318 15057287
13. Sonis S.T. Elting L.S. Keefe D. Peterson D.E. Schubert M. Hauer-Jensen M. Bekele B.N. Raber-Durlacher J. Donnelly J.P. Rubenstein E.B. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients Cancer 2004 100 1995 2025 10.1002/cncr.20162 15108222
14. Antonadou D. Pepelassi M. Synodinou M. Puglisi M. Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer Int. J. Radiat. Oncol. Biol. Phys. 2002 52 739 747 10.1016/S0360-3016(01)02683-9 11849797
15. Rades D. Fehlauer F. Bajrovic A. Mahlmann B. Richter E. Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients Radiother. Oncol. 2004 70 261 264 10.1016/j.radonc.2003.10.005 15064010
16. Oberoi S. Zamperlini-Netto G. Beyene J. Treister N.S. Sung L. Effect of prophylactic low level laser therapy on oral mucositis: A systematic review and meta-analysis PLoS ONE 2014 9 e107418 10.1371/journal.pone.0107418 25198431 PMC4157876
17. Peng J. Shi Y. Wang J. Wang F. Dan H. Xu H. Zeng X. Low-level laser therapy in the prevention and treatment of oral mucositis: A systematic review and meta-analysis Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2020 130 387 397.e389 10.1016/j.oooo.2020.05.014 32624448
18. Amiri Khosroshahi R. Talebi S. Travica N. Mohammadi H. Cryotherapy for oral mucositis in cancer: Review of systematic reviews and meta-analysis BMJ Support. Palliat. Care 2022 10.1136/spcare-2022-003636 36450589
19. Lai C.C. Chen S.Y. Tu Y.K. Ding Y.W. Lin J.J. Effectiveness of low level laser therapy versus cryotherapy in cancer patients with oral mucositis: Systematic review and network meta-analysis Crit. Rev. Oncol. Hematol. 2021 160 103276 10.1016/j.critrevonc.2021.103276 33716203
20. Elad S. Cheng K.K.F. Lalla R.V. Yarom N. Hong C. Logan R.M. Bowen J. Gibson R. Saunders D.P. Zadik Y. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy Cancer 2020 126 4423 4431 10.1002/cncr.33100 32786044 PMC7540329
21. Bensadoun R.J. Riesenbeck D. Lockhart P.B. Elting L.S. Spijkervet F.K. Brennan M.T. Trismus Section, Oral Care Study Group A systematic review of trismus induced by cancer therapies in head and neck cancer patients Support. Care Cancer 2010 18 1033 1038 10.1007/s00520-010-0847-4 20213237
22. Dijkstra P.U. Kalk W.W. Roodenburg J.L. Trismus in head and neck oncology: A systematic review Oral Oncol. 2004 40 879 889 10.1016/j.oraloncology.2004.04.003 15380165
23. Dijkstra P.U. Huisman P.M. Roodenburg J.L. Criteria for trismus in head and neck oncology Int. J. Oral Maxillofac. Surg. 2006 35 337 342 10.1016/j.ijom.2005.08.001 16280237
24. Louise Kent M. Brennan M.T. Noll J.L. Fox P.C. Burri S.H. Hunter J.C. Lockhart P.B. Radiation-induced trismus in head and neck cancer patients Support. Care Cancer 2008 16 305 309 10.1007/s00520-007-0345-5 17965892
25. Pauli N. Johnson J. Finizia C. Andrell P. The incidence of trismus and long-term impact on health-related quality of life in patients with head and neck cancer Acta Oncol. 2013 52 1137 1145 10.3109/0284186X.2012.744466 23193958
26. Lee L.Y. Chen S.C. Chen W.C. Huang B.S. Lin C.Y. Postradiation trismus and its impact on quality of life in patients with head and neck cancer Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2015 119 187 195 10.1016/j.oooo.2014.10.003 25487985
27. Gomez D.R. Zhung J.E. Gomez J. Chan K. Wu A.J. Wolden S.L. Pfister D.G. Shaha A. Shah J.P. Kraus D.H. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers Int. J. Radiat. Oncol. Biol. Phys. 2009 73 1096 1103 10.1016/j.ijrobp.2008.05.024 18707827
28. Chao K.S. Ozyigit G. Blanco A.I. Thorstad W.L. Deasy J.O. Haughey B.H. Spector G.J. Sessions D.G. Intensity-modulated radiation therapy for oropharyngeal carcinoma: Impact of tumor volume Int. J. Radiat. Oncol. Biol. Phys. 2004 59 43 50 10.1016/j.ijrobp.2003.08.004 15093897
29. Ingle C.J. Yip K. Caskie V. Dyson C. Ford A. Scrase C.D. Intensity modulated radiotherapy (IMRT) in the management of locally advanced oropharyngeal squamous cell carcinomata (SCC): Disease control and functional outcome using the therapy outcome measure (TOM) score-report from a single U.K. institution Head Neck Oncol. 2010 2 28 10.1186/1758-3284-2-28 20946673 PMC2976729
30. Hsieh L.C. Chen J.W. Wang L.Y. Tsang Y.M. Shueng P.W. Liao L.J. Lo W.C. Lin Y.C. Tseng C.F. Kuo Y.S. Predicting the severity and prognosis of trismus after intensity-modulated radiation therapy for oral cancer patients by magnetic resonance imaging PLoS ONE 2014 9 e92561 10.1371/journal.pone.0092561 24658376 PMC3962418
31. Rao S.D. Saleh Z.H. Setton J. Tam M. McBride S.M. Riaz N. Deasy J.O. Lee N.Y. Dose-volume factors correlating with trismus following chemoradiation for head and neck cancer Acta Oncol. 2016 55 99 104 10.3109/0284186X.2015.1037864 25920361 PMC4784420
32. Kamstra J.I. Dijkstra P.U. van Leeuwen M. Roodenburg J.L. Langendijk J.A. Mouth opening in patients irradiated for head and neck cancer: A prospective repeated measures study Oral Oncol. 2015 51 548 555 10.1016/j.oraloncology.2015.01.016 25703798
33. Lindblom U. Garskog O. Kjellen E. Laurell G. Levring Jaghagen E. Wahlberg P. Zackrisson B. Nilsson P. Radiation-induced trismus in the ARTSCAN head and neck trial Acta Oncol. 2014 53 620 627 10.3109/0284186X.2014.892209 24669774
34. Teguh D.N. Levendag P.C. Voet P. van der Est H. Noever I. de Kruijf W. van Rooij P. Schmitz P.I. Heijmen B.J. Trismus in patients with oropharyngeal cancer: Relationship with dose in structures of mastication apparatus Head Neck 2008 30 622 630 10.1002/hed.20760 18213726
35. Kamstra J.I. van Leeuwen M. Roodenburg J.L.N. Dijkstra P.U. Exercise therapy for trismus secondary to head and neck cancer: A systematic review Head Neck 2017 39 2352 2362 10.1002/hed.24859 29044879
36. Dijkstra P.U. Sterken M.W. Pater R. Spijkervet F.K. Roodenburg J.L. Exercise therapy for trismus in head and neck cancer Oral Oncol. 2007 43 389 394 10.1016/j.oraloncology.2006.04.003 16979926
37. Dijkstra P.U. Dynasplint for the management of trismus after treatment of upper aerodigestive tract cancer: A retrospective study Ear. Nose Throat J. 2012 91 E35 22829046
38. Kamstra J.I. Roodenburg J.L. Beurskens C.H. Reintsema H. Dijkstra P.U. TheraBite exercises to treat trismus secondary to head and neck cancer Support. Care Cancer 2013 21 951 957 10.1007/s00520-012-1610-9 23052916 PMC3584250
39. Bjordal K. Kaasa S. Mastekaasa A. Quality of life in patients treated for head and neck cancer: A follow-up study 7 to 11 years after radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 1994 28 847 856 10.1016/0360-3016(94)90104-X 8138437
40. Wijers O.B. Levendag P.C. Braaksma M.M. Boonzaaijer M. Visch L.L. Schmitz P.I. Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long-term survivors Head Neck 2002 24 737 747 10.1002/hed.10129 12203798
41. Coppes R.P. Zeilstra L.J. Kampinga H.H. Konings A.W. Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists Br. J. Cancer 2001 85 1055 1063 10.1054/bjoc.2001.2038 11592779 PMC2375094
42. Lombaert I.M. Brunsting J.F. Wierenga P.K. Faber H. Stokman M.A. Kok T. Visser W.H. Kampinga H.H. de Haan G. Coppes R.P. Rescue of salivary gland function after stem cell transplantation in irradiated glands PLoS ONE 2008 3 e2063 10.1371/journal.pone.0002063 18446241 PMC2329592
43. Chao K.S. Deasy J.O. Markman J. Haynie J. Perez C.A. Purdy J.A. Low D.A. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results Int. J. Radiat. Oncol. Biol. Phys. 2001 49 907 916 10.1016/S0360-3016(00)01441-3 11240231
44. Leslie M.D. Dische S. The early changes in salivary gland function during and after radiotherapy given for head and neck cancer Radiother. Oncol. 1994 30 26 32 10.1016/0167-8140(94)90006-X 8153377
45. Blanco A.I. Chao K.S. El Naqa I. Franklin G.E. Zakarian K. Vicic M. Deasy J.O. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 2005 62 1055 1069 10.1016/j.ijrobp.2004.12.076 15990009
46. Beetz I. Steenbakkers R.J. Chouvalova O. Leemans C.R. Doornaert P. van der Laan B.F. Christianen M.E. Vissink A. Bijl H.P. van Luijk P. The QUANTEC criteria for parotid gland dose and their efficacy to prevent moderate to severe patient-rated xerostomia Acta Oncol. 2014 53 597 604 10.3109/0284186X.2013.831186 23998646
47. Moiseenko V. Wu J. Hovan A. Saleh Z. Apte A. Deasy J.O. Harrow S. Rabuka C. Muggli A. Thompson A. Treatment planning constraints to avoid xerostomia in head-and-neck radiotherapy: An independent test of QUANTEC criteria using a prospectively collected dataset Int. J. Radiat. Oncol. Biol. Phys. 2012 82 1108 1114 10.1016/j.ijrobp.2011.04.020 21640505 PMC3192313
48. Cheng C.Q. Xu H. Liu L. Wang R.N. Liu Y.T. Li J. Zhou X.K. Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis J. Am. Dent. Assoc. 2016 147 236 243 10.1016/j.adaj.2015.09.014 26563850
49. Mercadante V. Jensen S.B. Smith D.K. Bohlke K. Bauman J. Brennan M.T. Coppes R.P. Jessen N. Malhotra N.K. Murphy B. Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline J. Clin. Oncol. 2021 39 2825 2843 10.1200/JCO.21.01208 34283635
50. Marx R.E. Osteoradionecrosis: A new concept of its pathophysiology J. Oral Maxillofac. Surg. 1983 41 283 288 10.1016/0278-2391(83)90294-X 6572704
51. Epstein J.B. Wong F.L. Stevenson-Moore P. Osteoradionecrosis: Clinical experience and a proposal for classification J. Oral Maxillofac. Surg. 1987 45 104 110 10.1016/0278-2391(87)90399-5 3468211
52. van Merkesteyn J.P. Balm A.J. Bakker D.J. Borgmeyer-Hoelen A.M. Hyperbaric oxygen treatment of osteoradionecrosis of the mandible with repeated pathologic fracture. Report of a case Oral Surg. Oral Med. Oral Pathol. 1994 77 461 464 10.1016/0030-4220(94)90224-0 8028868
53. Store G. Boysen M. Mandibular osteoradionecrosis: Clinical behaviour and diagnostic aspects Clin. Otolaryngol. Allied Sci. 2000 25 378 384 10.1046/j.1365-2273.2000.00367.x 11012651
54. Lee I.J. Koom W.S. Lee C.G. Kim Y.B. Yoo S.W. Keum K.C. Kim G.E. Choi E.C. Cha I.H. Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients Int. J. Radiat. Oncol. Biol. Phys. 2009 75 1084 1091 10.1016/j.ijrobp.2008.12.052 19327914
55. Mendenhall W.M. Mandibular osteoradionecrosis J. Clin. Oncol. 2004 22 4867 4868 10.1200/JCO.2004.09.959 15520050
56. Oh H.K. Chambers M.S. Martin J.W. Lim H.J. Park H.J. Osteoradionecrosis of the mandible: Treatment outcomes and factors influencing the progress of osteoradionecrosis J. Oral Maxillofac. Surg. 2009 67 1378 1386 10.1016/j.joms.2009.02.008 19531406
57. Wahl M.J. Osteoradionecrosis prevention myths Int. J. Radiat. Oncol. Biol. Phys. 2006 64 661 669 10.1016/j.ijrobp.2005.10.021 16458773
58. Chronopoulos A. Zarra T. Troltzsch M. Mahaini S. Ehrenfeld M. Otto S. Osteoradionecrosis of the mandible: A ten year single-center retrospective study J. Cranio-Maxillofac. Surg. 2015 43 837 846 10.1016/j.jcms.2015.03.024 25939311
59. Tsai C.J. Hofstede T.M. Sturgis E.M. Garden A.S. Lindberg M.E. Wei Q. Tucker S.L. Dong L. Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer Int. J. Radiat. Oncol. Biol. Phys. 2013 85 415 420 10.1016/j.ijrobp.2012.05.032 22795804
60. Studer G. Bredell M. Studer S. Huber G. Glanzmann C. Risk profile for osteoradionecrosis of the mandible in the IMRT era Strahlenther. Onkol. 2016 192 32 39 10.1007/s00066-015-0875-6 26265308 PMC4705130
61. Lukens J.N. Lin A. Hahn S.M. Proton therapy for head and neck cancer Curr. Opin. Oncol. 2015 27 165 171 10.1097/CCO.0000000000000181 25811343
62. Studer G. Gratz K.W. Glanzmann C. Osteoradionecrosis of the mandibula in patients treated with different fractionations Strahlenther. Onkol. 2004 180 233 240 10.1007/s00066-004-1171-z 15057434
63. Shaw R. Butterworth C. Tesfaye B. Bickerstaff M. Dodd S. Smerdon G. Chauhan S. Brennan P. Webster K. McCaul J. HOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): A randomised controlled trial of hyperbaric oxygen to prevent osteoradionecrosis of the irradiated mandible: Study protocol for a randomised controlled trial Trials 2018 19 22 10.1186/s13063-017-2376-7 29316962 PMC5761154
64. Kolokythas A. Rasmussen J.T. Reardon J. Feng C. Management of osteoradionecrosis of the jaws with pentoxifylline-tocopherol: A systematic review of the literature and meta-analysis Int. J. Oral Maxillofac. Surg. 2019 48 173 180 10.1016/j.ijom.2018.08.007 30205911
65. Ribeiro G.H. Minamisako M.C. Rath I. Santos A.M.B. Simoes A. Pereira K.C.R. Grando L.J. Osteoradionecrosis of the jaws: Case series treated with adjuvant low-level laser therapy and antimicrobial photodynamic therapy J. Appl. Oral Sci. 2018 26 e20170172 10.1590/1678-7757-2017-0172 29791570 PMC5953563
66. Cha Y.H. Hong N. Rhee Y. Cha I.H. Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw Osteoporos. Int. 2018 29 987 992 10.1007/s00198-017-4343-2 29249017
67. Hicks J. Flaitz C. Rhabdomyosarcoma of the head and neck in children Oral Oncol. 2002 38 450 459 10.1016/S1368-8375(01)00105-1 12110339
68. Maguire A. Craft A.W. Evans R.G. Amineddine H. Kernahan J. Macleod R.I. Murray J.J. Welbury R.R. The long-term effects of treatment on the dental condition of children surviving malignant disease Cancer 1987 60 2570 2575 10.1002/1097-0142(19871115)60:10<2570::AID-CNCR2820601037>3.0.CO;2-Q 3664436
69. Raney R.B. Asmar L. Vassilopoulou-Sellin R. Klein M.J. Donaldson S.S. Green J. Heyn R. Wharam M. Glicksman A.S. Gehan E.A. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and-III. IRS Group of the Children’s Cancer Group and the Pediatric Oncology Group Med. Pediatr. Oncol. 1999 33 362 371 10491544 10.1002/(sici)1096-911x(199910)33:4<362::aid-mpo4>3.0.co;2-i
70. Kaste S.C. Hopkins K.P. Bowman L.C. Dental abnormalities in long-term survivors of head and neck rhabdomyosarcoma Med. Pediatr. Oncol. 1995 25 96 101 10.1002/mpo.2950250209 7603407
71. Kaste S.C. Goodman P. Leisenring W. Stovall M. Hayashi R.J. Yeazel M. Beiraghi S. Hudson M.M. Sklar C.A. Robison L.L. Impact of radiation and chemotherapy on risk of dental abnormalities: A report from the Childhood Cancer Survivor Study Cancer 2009 115 5817 5827 10.1002/cncr.24670 19834960 PMC3754878
72. Kaste S.C. Hopkins K.P. Jenkins J.J. 3rd Abnormal odontogenesis in children treated with radiation and chemotherapy: Imaging findings AJR Am. J. Roentgenol. 1994 162 1407 1411 10.2214/ajr.162.6.8192008 8192008
73. Coleman R.E. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies Cancer Treat. Rev. 2001 27 165 176 10.1053/ctrv.2000.0210 11417967
74. Hofbauer L.C. Rachner T.D. Coleman R.E. Jakob F. Endocrine aspects of bone metastases Lancet Diabetes Endocrinol. 2014 2 500 512 10.1016/S2213-8587(13)70203-1 24880565
75. Fleissig Y. Regev E. Lehman H. Sunitinib related osteonecrosis of jaw: A case report Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012 113 e1 e3 10.1016/j.tripleo.2011.06.023 22676833
76. Estilo C.L. Fornier M. Farooki A. Carlson D. Bohle G. 3rd Huryn J.M. Osteonecrosis of the jaw related to bevacizumab J. Clin. Oncol. 2008 26 4037 4038 10.1200/JCO.2007.15.5424 18711196
77. Kim D.W. Jung Y.S. Park H.S. Jung H.D. Osteonecrosis of the jaw related to everolimus: A case report Br. J. Oral Maxillofac. Surg. 2013 51 e302 e304 10.1016/j.bjoms.2013.09.008 24094895
78. Owosho A.A. Scordo M. Yom S.K. Randazzo J. Chapman P.B. Huryn J.M. Estilo C.L. Osteonecrosis of the jaw a new complication related to Ipilimumab Oral Oncol. 2015 51 e100 e101 10.1016/j.oraloncology.2015.08.014 26421864 PMC4784100
79. Mawardi H. Enzinger P. McCleary N. Manon R. Villa A. Treister N. Woo S.B. Osteonecrosis of the jaw associated with ziv-aflibercept J. Gastrointest. Oncol. 2016 7 E81 E87 10.21037/jgo.2016.05.07 28078129 PMC5177584
80. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic J. Oral Maxillofac. Surg. 2003 61 1115 1117 10.1016/S0278-2391(03)00720-1 12966493
81. Nicolatou-Galitis O. Kouri M. Papadopoulou E. Vardas E. Galiti D. Epstein J.B. Elad S. Campisi G. Tsoukalas N. Bektas-Kayhan K. Osteonecrosis of the jaw related to non-antiresorptive medications: A systematic review Support. Care Cancer 2019 27 383 394 10.1007/s00520-018-4501-x 30353228
82. Ruggiero S.L. Dodson T.B. Aghaloo T. Carlson E.R. Ward B.B. Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update J. Oral Maxillofac. Surg. 2022 80 920 943 10.1016/j.joms.2022.02.008 35300956
83. Owosho A.A. Liang S.T.Y. Sax A.Z. Wu K. Yom S.K. Huryn J.M. Estilo C.L. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2018 125 440 445 10.1016/j.oooo.2018.02.003 29580668 PMC7518027
84. Hallmer F. Andersson G. Gotrick B. Warfvinge G. Anderud J. Bjornland T. Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2018 126 477 485 10.1016/j.oooo.2018.08.015 30249535
85. Saad F. Brown J.E. Van Poznak C. Ibrahim T. Stemmer S.M. Stopeck A.T. Diel I.J. Takahashi S. Shore N. Henry D.H. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Ann. Oncol. 2012 23 1341 1347 10.1093/annonc/mdr435 21986094
86. Kyrgidis A. Vahtsevanos K. Koloutsos G. Andreadis C. Boukovinas I. Teleioudis Z. Patrikidou A. Triaridis S. Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients J. Clin. Oncol. 2008 26 4634 4638 10.1200/JCO.2008.16.2768 18574158
87. Mozzati M. Arata V. Gallesio G. Tooth extraction in patients on zoledronic acid therapy Oral Oncol. 2012 48 817 821 10.1016/j.oraloncology.2012.03.009 22483860
88. Yamazaki T. Yamori M. Ishizaki T. Asai K. Goto K. Takahashi K. Nakayama T. Bessho K. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: A cohort study Int. J. Oral Maxillofac. Surg. 2012 41 1397 1403 10.1016/j.ijom.2012.06.020 22840716
89. Scoletta M. Arata V. Arduino P.G. Lerda E. Chiecchio A. Gallesio G. Scully C. Mozzati M. Tooth extractions in intravenous bisphosphonate-treated patients: A refined protocol J. Oral Maxillofac. Surg. 2013 71 994 999 10.1016/j.joms.2013.01.006 23434159
90. Gnant M. Mlineritsch B. Stoeger H. Luschin-Ebengreuth G. Knauer M. Moik M. Jakesz R. Seifert M. Taucher S. Bjelic-Radisic V. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Ann. Oncol. 2015 26 313 320 10.1093/annonc/mdu544 25403582
91. Gnant M. Pfeiler G. Dubsky P.C. Hubalek M. Greil R. Jakesz R. Wette V. Balic M. Haslbauer F. Melbinger E. Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial Lancet 2015 386 433 443 10.1016/S0140-6736(15)60995-3 26040499
92. Ng T.L. Tu M.M. Ibrahim M.F.K. Basulaiman B. McGee S.F. Srikanthan A. Fernandes R. Vandermeer L. Stober C. Sienkiewicz M. Long-term impact of bone-modifying agents for the treatment of bone metastases: A systematic review Support. Care Cancer 2021 29 925 943 10.1007/s00520-020-05556-0 32535678
93. Bramati A. Girelli S. Farina G. Dazzani M.C. Torri V. Moretti A. Piva S. Dimaiuta M. La Verde N. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases J. Bone Miner. Metab. 2015 33 119 124 10.1007/s00774-014-0566-x 24553860
94. Bonacina R. Mariani U. Villa F. Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: A review of 282 patients J. Can. Dent. Assoc. 2011 77 b147 22129778
95. Dimopoulos M.A. Kastritis E. Bamia C. Melakopoulos I. Gika D. Roussou M. Migkou M. Eleftherakis-Papaiakovou E. Christoulas D. Terpos E. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann. Oncol. 2009 20 117 120 10.1093/annonc/mdn554 18689864
96. Ripamonti C.I. Lucchesi M. Giusti R. Prevention and management of osteonecrosis of the jaw secondary to bone-targeted therapy in patients with kidney cancer Curr. Opin. Support. Palliat. Care 2016 10 273 280 10.1097/SPC.0000000000000219 27380219
97. Epstein M.S. Wicknick F.W. Epstein J.B. Berenson J.R. Gorsky M. Management of bisphosphonate-associated osteonecrosis: Pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010 110 593 596 10.1016/j.tripleo.2010.05.067 20955948
98. Owosho A.A. Estilo C.L. Huryn J.M. Yom S.K. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: An observational retrospective study of initial case series Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2016 122 455 459 10.1016/j.oooo.2016.06.019 27651287 PMC5454806
99. Vescovi P. Meleti M. Merigo E. Manfredi M. Fornaini C. Guidotti R. Nammour S. Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy Med. Oral Patol. Oral Cir. Bucal. 2013 18 e680 e685 10.4317/medoral.18812 23524436 PMC3731098
100. Vescovi P. Giovannacci I. Merigo E. Meleti M. Manfredi M. Fornaini C. Nammour S. Tooth extractions in high-risk patients under bisphosphonate therapy and previously affected with osteonecrosis of the jaws: Surgical protocol supported by low-level laser therapy J. Craniofac. Surg. 2015 26 696 699 10.1097/SCS.0000000000001665 25915674
101. Sim I.W. Borromeo G.L. Tsao C. Hardiman R. Hofman M.S. Papatziamos Hjelle C. Siddique M. Cook G.J.R. Seymour J.F. Ebeling P.R. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial J. Clin. Oncol. 2020 38 2971 2980 10.1200/JCO.19.02192 32614699
102. Yarom N. Shapiro C.L. Peterson D.E. Van Poznak C.H. Bohlke K. Ruggiero S.L. Migliorati C.A. Khan A. Morrison A. Anderson H. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline J. Clin. Oncol. 2019 37 2270 2290 10.1200/JCO.19.01186 31329513
103. Copelan E.A. Hematopoietic stem-cell transplantation N. Engl. J. Med. 2006 354 1813 1826 10.1056/NEJMra052638 16641398
104. Elad S. Thierer T. Bitan M. Shapira M.Y. Meyerowitz C. A decision analysis: The dental management of patients prior to hematology cytotoxic therapy or hematopoietic stem cell transplantation Oral Oncol. 2008 44 37 42 10.1016/j.oraloncology.2006.12.006 17307024
105. Chaudhry H.M. Bruce A.J. Wolf R.C. Litzow M.R. Hogan W.J. Patnaik M.S. Kremers W.K. Phillips G.L. Hashmi S.K. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review Biol. Blood Marrow Transplant. 2016 22 605 616 10.1016/j.bbmt.2015.09.014 26409924
106. van Leeuwen S.J.M. Potting C.M.J. Huysmans M. Blijlevens N.M.A. Salivary Changes before and after Hematopoietic Stem Cell Transplantation: A Systematic Review Biol. Blood Marrow Transplant. 2019 25 1055 1061 10.1016/j.bbmt.2019.01.026 30710684
107. Baird K. Pavletic S.Z. Chronic graft versus host disease Curr. Opin. Hematol 2006 13 426 435 10.1097/01.moh.0000245689.47333.ff 17053454
108. Imanguli M.M. Alevizos I. Brown R. Pavletic S.Z. Atkinson J.C. Oral graft-versus-host disease Oral Dis. 2008 14 396 412 10.1111/j.1601-0825.2008.01448.x 18593456 PMC2565862
109. Bustillos H. Indorf A. Alwan L. Thompson J. Jung L. Xerostomia: An immunotherapy-related adverse effect in cancer patients Support. Care Cancer 2022 30 1681 1687 10.1007/s00520-021-06535-9 34562169
110. Lederhandler M.H. Ho A. Brinster N. Ho R.S. Liebman T.N. Lo Sicco K. Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab J. Drugs Dermatol. 2018 17 807 809 30005106
111. Owosho A.A. Randazzo J. Rosen E.B. Estilo C.L. Huryn J.M. Chi P. Yom S.K. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab Oral Oncol. 2016 63 e1 e3 10.1016/j.oraloncology.2016.09.011 27743938 PMC5599103